Ancora Biotech LLC

About Ancora Biotech LLC

Ancora Biotech is a privately-owned startup that focuses on the development of innovative biotherapeutics for the treatment of B cell cancers, metabolic diseases, and chronic hepatitis B infections. The company's business model revolves around the clinical development of three multi-specific antibodies, each held in separate spin-offs.

The first, TeneoTwo, is developing TNB-486, a T cell engager designed to treat B cell cancers safely and effectively. The second, TeneoFour, is working on TNB-738, an enzyme inhibitor aimed at treating inflammatory and metabolic disorders in older adults. The third, TeneoTen, is developing a T cell engager for the curative treatment of chronic hepatitis B infections.

Ancora Biotech operates in the biotechnology and pharmaceutical market, serving a wide range of clients, including healthcare providers and patients suffering from the diseases it targets. The company generates revenue through the development and commercialization of its therapeutic antibodies.

Ancora Biotech is backed by former executives and shareholders of Teneobio, including Lightspeed Venture Partners and Sutter Hill Ventures, who oversee the manufacturing and clinical development of these assets. The company has also attracted significant investment from venture capitalists, leading to profitable deals, including a notable one with AstraZeneca.